Dinutuximab beta
Phase 3Monoclonal antibody
BeiGeneDinutuximab beta is one of 141 biologic programs targeting High-Risk Neuroblastoma. It is currently in Phase 3.
4
Indications
11
Total Trials
8
Active Trials
140
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
139 competitors in Trial
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Eloxatin
TevaPhase 3
Camptosar
PfizerPhase 3
Perjeta
RochePhase 3
Vectibix
AmgenPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Tarceva
OOSI Pharmaceuticals
Phase 3
Herceptin
OOrganon and Co
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neuroblastoma7 trials
Show 4 more trials
Trial1 trial
International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma
Not yet recruiting·—·Phase 1·NCT06839703·18 enrolled
Soft Tissue Sarcoma1 trial
Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas
Recruiting·NN.N. Petrov National Medical Research Center of Oncology·Phase 3·NCT06669013·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dinutuximab beta. EMBL-EBI & Wellcome Sanger Institute.
- [4]